United Therapeutics Corp. announced that the FDA has approved the Tyvaso dry powder inhaler for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability.
Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler approved by the FDA for use in PAH and pulmonary hypertension-associated ILD, according to a company press release.
“Tyvaso DPI is one of the easiest ways for patients to administer a prostacyclin, delivering the proven efficacy